[go: up one dir, main page]

SG11201805927YA - Spiroheptane salicylamides and related compounds as inhibitors of rock - Google Patents

Spiroheptane salicylamides and related compounds as inhibitors of rock

Info

Publication number
SG11201805927YA
SG11201805927YA SG11201805927YA SG11201805927YA SG11201805927YA SG 11201805927Y A SG11201805927Y A SG 11201805927YA SG 11201805927Y A SG11201805927Y A SG 11201805927YA SG 11201805927Y A SG11201805927Y A SG 11201805927YA SG 11201805927Y A SG11201805927Y A SG 11201805927YA
Authority
SG
Singapore
Prior art keywords
pennington
new jersey
myers squibb
co7d
bristol
Prior art date
Application number
SG11201805927YA
Inventor
Ii Leon M Smith
Vladimir Ladziata
Indawati Delucca
Donald Pinto
Michael J Orwat
Andrew K Dilger
Kumar Balashanmuga Pabbisetty
Wu Yang
Scott A Shaw
Peter W Glunz
Manoranjan Panda
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11201805927YA publication Critical patent/SG11201805927YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, - Organization 11111111011110111010101111101011111011101110111101111011001101111101111011111 International Bureau ... .... ..Yjd (10) International Publication Number (43) International Publication Date ..... .... WO 2017/123860 Al 20 July 2017 (20.07.2017) WIPO I PCT (51) International Patent Classification: New Jersey 08534 (US). LADZIATA, Vladimir; c/o Bris- CO7D 401/14 (2006.01) CO7D 401/12 (2006.01) tol-Myers Squibb Company, 311 Pennington-Rocky Hill A61K 31/437 (2006.01) CO7D 413/12 (2006.01) Road, Pennington, New Jersey 08534 (US). DELUCCA, A61K 31/4427 (2006.01) CO7D 471/04 (2006.01) Indawati; c/o Bristol-Myers Squibb Company, 311 Pen- CO7D 231/12 (2006.01) CO7D 471/12 (2006.01) nington-Rocky Hill Road, Pennington, New Jersey 08534 CO7D 231/18 (2006.01) CO7D 513/04 (2006.01) (US). PINTO, Donald, J., P.; c/o Bristol-Myers Squibb CO7D 231/54 (2006.01) CO7D 213/64 (2006.01) Company, 311 Pennington-Rocky Hill Road, Pennington, (21) New Jersey 08534 (US). ORWAT, Michael J.; c/o Bris- International Application Number: PCT/US2017/013323 tol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534 (US). DILGER, An- (22) International Filing Date: drew K.; c/o Bristol-Myers Squibb Company, 311 Pen- 13 January 2017 (13.01.2017) nington-Rocky Hill Road, Pennington, New Jersey 08534 (US). PABBISETTY, Kumar Balashanmuga; c/o Bris- tol-Myers Squibb Company, 311 Pennington-Rocky Hill (26) Publication Language: English Road, Pennington, New Jersey 08534 (US). YANG, Wu; c/o Bristol-Myers Squibb Company, 311 Penning- (30) Priority Data: ton -Rocky Hill Road, Pennington, New Jersey 08534 (US). 62/278,122 13 January 2016 (13.01.2016) US SHAW, Scott A.; c/o Bristol-Myers Squibb Company, 311 (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY Pennington-Rocky Hill Road, Pennington, New Jersey [US/US]; Route 206 and Province Line Road, Princeton, 08534 (US). GLUNZ, Peter W.; c/o Bristol-Myers Squibb New Jersey 08543 (US). Company, 311 Pennington-Rocky Hill Road, Pennington, New Jersey 08534 (US). PANDA, Manoranjan; c/o SYN- = (72) Inventors: SMITH II, Leon M.; c/o Bristol-Myers Squibb GENE INTERNATIONAL LIMITED, Biocon Special Company, 311 Pennington-Rocky Hill Road, Pennington, Economic Zone, Biocon Park, Plot No. 2 & 3, Bommas- [Continued on next page] (54) Title: SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK (57) : The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutic- () ally-acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhib- R 6 , A itors. This invention also relates to pharmaceutical composi- N R1 tions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, R2 autoimmune, fibrotic, and/or inflammatory disorders using the same. R 13 --.....„ _ R I 3 ---- R 12 o 12 ix ......__ (I) R\" (R 3 0_4 1-1 NH2 © GC en ei ,-1 IN ,-1 © ei O WO 2017/123860 Al MIDEDIMOMOIDEIR010130H01110MEHMEMOVOIMIE andra Industrial Area IV Phase, Jigani Line Road Born- (84) Designated States (unless otherwise indicated, for every (74) masandra Bangalore, Karnataka 560 099 (IN). Agents: LIU, Hong et al.; Bristol-Myers Squibb Corn- pany, Route 206 & Province Line Road, Princeton, New Jersey 08543 (US). kind of regional protection available): ARIPO (BW, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, TZ, UG, ZM ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, ur , TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, GH, SZ, DE, LT, (81) Designated States (unless otherwise indicated, for every LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, kind of national protection available): AE, AG, AL, AM, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, GN, GQ, GW, KM, ML, MR, NE, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, Declarations under Rule 4.17: SN, TD, TG). SE, GA, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, — of inventorship (Rule 4.17(iv)) KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, Published: LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, — with international search report (Art. 21(3)) QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
SG11201805927YA 2016-01-13 2017-01-13 Spiroheptane salicylamides and related compounds as inhibitors of rock SG11201805927YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662278122P 2016-01-13 2016-01-13
PCT/US2017/013323 WO2017123860A1 (en) 2016-01-13 2017-01-13 Spiroheptane salicylamides and related compounds as inhibitors of rock

Publications (1)

Publication Number Publication Date
SG11201805927YA true SG11201805927YA (en) 2018-08-30

Family

ID=57907009

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805927YA SG11201805927YA (en) 2016-01-13 2017-01-13 Spiroheptane salicylamides and related compounds as inhibitors of rock

Country Status (29)

Country Link
US (2) US10611776B2 (en)
EP (2) EP3402790B1 (en)
JP (2) JP6976953B2 (en)
KR (1) KR102725741B1 (en)
CN (1) CN108699038B (en)
AR (1) AR107354A1 (en)
AU (2) AU2017206820B2 (en)
BR (1) BR112018013780B1 (en)
CA (1) CA3010900A1 (en)
CL (1) CL2018001899A1 (en)
CO (1) CO2018008173A2 (en)
CY (1) CY1124858T1 (en)
EA (1) EA036172B1 (en)
ES (1) ES2898698T3 (en)
HR (1) HRP20211888T1 (en)
HU (1) HUE057455T2 (en)
IL (1) IL260448B (en)
LT (1) LT3402790T (en)
MA (2) MA55633A (en)
MX (2) MX382434B (en)
PL (1) PL3402790T3 (en)
PT (1) PT3402790T (en)
RS (1) RS62690B1 (en)
SG (1) SG11201805927YA (en)
SI (1) SI3402790T1 (en)
SM (1) SMT202100660T1 (en)
TW (1) TWI730032B (en)
UY (1) UY37073A (en)
WO (1) WO2017123860A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107406426B (en) 2015-01-09 2020-11-20 百时美施贵宝公司 Cyclic ureas as ROCK inhibitors
EP3268360B1 (en) 2015-03-09 2019-04-24 Bristol-Myers Squibb Company Lactams as inhibitors of rock
HUE049134T2 (en) 2016-01-13 2020-08-28 Gruenenthal Gmbh 3- (Carboxymethyl) -8-amino-2-oxo-1,3-diazaspiro [4.5] decane derivatives
WO2017121647A1 (en) 2016-01-13 2017-07-20 Grünenthal GmbH 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
CN108602777B (en) 2016-01-13 2022-05-03 格吕伦塔尔有限公司 3- ((hetero-) aryl) -alkyl-8-amino-2-oxo-1, 3-aza-spiro- [4.5] -decane derivative
UY37073A (en) * 2016-01-13 2017-07-31 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware SPIROHEPTAN SALICILAMIDES AND RELATED COMPOUNDS AS ROCK INHIBITORS, AND THE COMPOSITIONS CONTAINING THEM
EA034898B1 (en) 2016-01-13 2020-04-03 Грюненталь Гмбх 8-amino-2-oxo-1,3-diaza-spiro[4.5]decane derivatives
BR112018068703B1 (en) 2016-03-16 2024-02-06 Kura Oncology, Inc. REPLACED MENIN-MLL INHIBITORS AND METHODS OF USE
US10562887B2 (en) 2016-05-27 2020-02-18 Bristol-Myers Squibb Company Triazolones and tetrazolones as inhibitors of ROCK
JP6903731B2 (en) 2016-07-07 2021-07-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Lactam, cyclic urea, and carbamate as potent and selective ROCK inhibitors, and triazolone derivatives
JP7113810B2 (en) 2016-07-07 2022-08-05 ブリストル－マイヤーズ スクイブ カンパニー Spirolactam as a ROCK inhibitor
JP7155102B2 (en) 2016-07-07 2022-10-18 ブリストル－マイヤーズ スクイブ カンパニー Spiro-fused ring ureas as ROCK inhibitors
ES2829400T3 (en) 2016-11-30 2021-05-31 Bristol Myers Squibb Co Tricyclic Rho kinase inhibitors
WO2019014304A1 (en) * 2017-07-12 2019-01-17 Bristol-Myers Squibb Company Spiroheptanyl hydantoins as rock inhibitors
ES2894128T3 (en) * 2017-07-12 2022-02-11 Bristol Myers Squibb Co ROCK 5,6- or 6,6-membered bicyclic aminoheterocyclic and 5-membered aminoheterocyclic inhibitors for the treatment of heart failure
US12060341B2 (en) 2017-07-12 2024-08-13 Bristol-Myers Squibb Company Spiroheptanyl hydantoins as ROCK inhibitors
EP3652164B1 (en) 2017-07-12 2023-06-21 Bristol-Myers Squibb Company Phenylacetamides as inhibitors of rock
TW201908293A (en) 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 5 members of ROCK inhibitor and bicyclic heterocyclic guanamine
TW201920170A (en) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 Substituted MENIN-MLL inhibitor and method of use
EP3704121B1 (en) 2017-11-03 2022-12-21 Bristol-Myers Squibb Company Diazaspiro rock inhibitors
CA3096894A1 (en) * 2018-04-17 2019-10-24 Tempest Therapeutics, Inc. Bicyclic carboxamides and methods of use thereof
EP4431596A1 (en) 2021-11-11 2024-09-18 The Doshisha Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation
JP2023120893A (en) 2022-02-18 2023-08-30 キヤノン株式会社 Holding device, lithographic apparatus and method of manufacturing an article
EP4554931A1 (en) * 2022-07-12 2025-05-21 Adama Makhteshim Ltd. Process for preparing substituted benzamides
WO2024229439A2 (en) * 2023-05-03 2024-11-07 The University Of Chicago Inhibitors of nsun1- and nsun2-mediated active structures
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (en) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025247783A1 (en) 2024-05-29 2025-12-04 Syngenta Crop Protection Ag Pesticidally active dihydro-benzoxazinone compounds
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025676A4 (en) * 2006-06-08 2011-06-15 Ube Industries NEW INDAZOLE DERIVATIVE HAVING A SPIRO CYCLIC STRUCTURE IN A SIDE CHAIN
EP2068878B1 (en) 2006-09-20 2019-04-10 Aerie Pharmaceuticals, Inc. Rho kinase inhibitors
NZ577980A (en) * 2006-12-27 2012-01-12 Sanofi Aventis Cycloalkylamine substituted isoquinolone derivatives
CL2007003874A1 (en) 2007-01-03 2008-05-16 Boehringer Ingelheim Int COMPOUNDS DERIVED FROM BENZAMIDA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT CARDIOVASCULAR DISEASES, HYPERTENSION, ATEROSCLEROSIS, RESTENOSIS, ICTUS, HEART FAILURE, ISCHEMICAL INJURY, HYPERTENSION
NZ586335A (en) * 2007-12-26 2011-08-26 Sanofi Aventis Process for the preparation of 6-substituted-1-(2h)-isoquinolinones
AU2011329233A1 (en) 2010-11-15 2013-05-23 Abbvie Deutschland Gmbh & Co Kg NAMPT and ROCK inhibitors
TW201443023A (en) 2013-01-18 2014-11-16 必治妥美雅史谷比公司 Phthalazinones and isoquinolinones as ROCK inhibitors
TW201444798A (en) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
US9828345B2 (en) 2013-02-28 2017-11-28 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
TW201506024A (en) 2013-07-02 2015-02-16 必治妥美雅史谷比公司 Tricyclic carboxamide derivatives as potent ROCK inhibitors
WO2015002926A1 (en) 2013-07-02 2015-01-08 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
US9902702B2 (en) 2014-07-15 2018-02-27 Bristol-Myers Squibb Company Spirocycloheptanes as inhibitors of rock
JP6633618B2 (en) 2014-08-21 2020-01-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Tideback benzamide derivatives as potent ROCK inhibitors
CN107406426B (en) 2015-01-09 2020-11-20 百时美施贵宝公司 Cyclic ureas as ROCK inhibitors
EP3268360B1 (en) 2015-03-09 2019-04-24 Bristol-Myers Squibb Company Lactams as inhibitors of rock
UY37073A (en) * 2016-01-13 2017-07-31 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware SPIROHEPTAN SALICILAMIDES AND RELATED COMPOUNDS AS ROCK INHIBITORS, AND THE COMPOSITIONS CONTAINING THEM
US10562887B2 (en) 2016-05-27 2020-02-18 Bristol-Myers Squibb Company Triazolones and tetrazolones as inhibitors of ROCK
JP7155102B2 (en) 2016-07-07 2022-10-18 ブリストル－マイヤーズ スクイブ カンパニー Spiro-fused ring ureas as ROCK inhibitors
JP7113810B2 (en) 2016-07-07 2022-08-05 ブリストル－マイヤーズ スクイブ カンパニー Spirolactam as a ROCK inhibitor
JP6903731B2 (en) 2016-07-07 2021-07-14 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Lactam, cyclic urea, and carbamate as potent and selective ROCK inhibitors, and triazolone derivatives
ES2829400T3 (en) 2016-11-30 2021-05-31 Bristol Myers Squibb Co Tricyclic Rho kinase inhibitors

Also Published As

Publication number Publication date
AU2017206820B2 (en) 2021-06-17
AU2017206820A1 (en) 2018-08-23
EA036172B1 (en) 2020-10-09
CA3010900A1 (en) 2017-07-20
CN108699038A (en) 2018-10-23
SMT202100660T1 (en) 2022-01-10
EP3954681A1 (en) 2022-02-16
MA43862A (en) 2021-06-02
RS62690B1 (en) 2021-12-31
BR112018013780B1 (en) 2023-12-19
CY1124858T1 (en) 2022-11-25
MA55633A (en) 2022-02-16
EP3402790A1 (en) 2018-11-21
SI3402790T1 (en) 2022-01-31
PT3402790T (en) 2021-11-22
US10829501B2 (en) 2020-11-10
IL260448B (en) 2020-09-30
EP3402790B1 (en) 2021-10-06
LT3402790T (en) 2021-12-10
MX382434B (en) 2025-03-13
AR107354A1 (en) 2018-04-18
WO2017123860A1 (en) 2017-07-20
ES2898698T3 (en) 2022-03-08
TWI730032B (en) 2021-06-11
KR102725741B1 (en) 2024-11-01
TW201726619A (en) 2017-08-01
CO2018008173A2 (en) 2018-08-21
UY37073A (en) 2017-07-31
US20190016735A1 (en) 2019-01-17
US10611776B2 (en) 2020-04-07
HRP20211888T1 (en) 2022-03-04
MX2021005311A (en) 2021-06-23
CN108699038B (en) 2021-04-16
JP7268116B2 (en) 2023-05-02
PL3402790T3 (en) 2022-01-24
US20200131200A1 (en) 2020-04-30
JP2022024019A (en) 2022-02-08
JP6976953B2 (en) 2021-12-08
EA201891557A1 (en) 2019-01-31
AU2021221872A1 (en) 2021-09-23
JP2019509978A (en) 2019-04-11
KR20180097749A (en) 2018-08-31
BR112018013780A2 (en) 2018-12-11
CL2018001899A1 (en) 2018-11-09
HUE057455T2 (en) 2022-05-28
MX2018008219A (en) 2018-09-07

Similar Documents

Publication Publication Date Title
SG11201805927YA (en) Spiroheptane salicylamides and related compounds as inhibitors of rock
SG11201900619XA (en) Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201907335UA (en) Aminotriazolopyridines as kinase inhibitors
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201407037UA (en) Catechol o-methyltransferase activity inhibiting compounds
SG11201910027YA (en) Bispecific antibody against ox40 and ctla-4
SG11201808990QA (en) Compositions for topical application of compounds
SG11201804934PA (en) Novel Compounds
SG11201408094YA (en) Neprilysin inhibitors
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201408678WA (en) Catalysts and methods for polyester production
SG11201807980QA (en) Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
SG11201907774VA (en) Sulfoximine glycosidase inhibitors
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201807949WA (en) Engineered immunoglobulins with altered fcrn binding
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201407372UA (en) Nampt inhibitors
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof